Single-Arm Phase II Trials with Heterogeneous Patient Populations: Binary and Survival Outcomes

The patient population for a phase II trial often consists of multiple subgroups, called subpopulations, with different prognosis although the study therapy is expected to be similarly beneficial for all subgroups. In this case, the final decision on the study treatment should be adjusted for the heterogeneity of the patient population.